Featured Publications
Global assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmInterferon regulatory factor 8Myeloid sarcomaDifferential diagnosisPlasmacytoid dendritic cell neoplasmDesmoplastic small round cell tumorSmall round cell tumorTriple-negative breast cancerStrong uniform expressionDendritic cell neoplasmBroad differential diagnosisNegative breast cancerRound cell tumorAbsence of CD34IHC expression patternsAcute monocytic leukemiaNovel immunohistochemical markerTypes of cancerRegulatory factor 8Cancer Genome AtlasNovel cancer biomarkersRetrospective studySynovial sarcomaCell tumorsPleomorphic sarcoma
2022
Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms.
Mata D, Xu M, Shanmugam V, Tukachinsky H, Schrock A, Ross J, Williams E, Montesion M, Decker B, Vergilio J, Oxnard G, Benhamida J. Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Journal Of Clinical Oncology 2022, 40: e19064-e19064. DOI: 10.1200/jco.2022.40.16_suppl.e19064.Peer-Reviewed Original ResearchComprehensive genomic profilingAcute myeloid leukemiaMyelodysplastic syndromeHistiocytic neoplasmsMyeloproliferative neoplasmsMyeloid neoplasiaAML casesMinimal residual disease testingPathogenic alterationsHybrid-capture next-generation sequencingSolid tumor diagnosisEvaluation of patientsRoutine clinical careRelevant genomic alterationsMonitoring of patientsUnique patient samplesRetrospective studyMyeloid leukemiaMyeloid neoplasmsClinical carePatientsKRAS G12AInsufficient tumorDisease testingPathway alterationsUtility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms.
Mata D, Shanmugam V, Decker B, Schrock A, Tukachinsky H, Williams E, Ross J, Montesion M, Oxnard G, Vergilio J, Xu M, Benhamida J. Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms. Journal Of Clinical Oncology 2022, 40: e19543-e19543. DOI: 10.1200/jco.2022.40.16_suppl.e19543.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaComprehensive genomic profilingNon-Hodgkin lymphomaPlasma cell neoplasmsPathogenic alterationsCell neoplasmsHybrid-capture next-generation sequencingLarge B-cell lymphomaRoutine clinical careActionable genomic alterationsGenomic alterationsHodgkin's lymphoma casesTumor biopsy specimensB-cell lymphomaPathogenic genomic alterationsUnique patient samplesRetrospective studyBiopsy specimensClinical careLymphoma casesTissue biopsiesLymphomaInsufficient tumorTumor DNAGenomic profiling